Pharmaceutical Investment Strategy- Product winning.doc

 PAGE \* MERGEFORMAT 13 Pharmaceutical Investment Strategy: ‘Product winning’ In China’s pharmaceutical market in clinical, commercial circulation and OTC terminals outside the main channel, derived from an individual or unit of this agent on the main channel for selling products, investment market in recent years the development has been much attention. Especially in recent years, clinical channel, OTC market, commercial distribution channels and the third terminal at the national supervision is increasing, and competitive pressures of the circumstances, the investment market, from the main channel due to the impact of a large number of commercial companies are increasingly being and manufacturers of the attention, through various means, channels, infiltration and development. The reason why such a value business investment market, in addition to state supervision of its macroeconomic environment, the less perfect, low cost of entry other than (individuals can operate without a large capital investment and fixed place of business), the most important One aspect is the investment markets, a higher operating profit, often their profits from product sales by other mainstream channels several times and even a few times, could not help but arouses envy. Here leads to a problem, the dominant factor in investment market operations, what is? Whether you offer a rebate to customers how high the market more perfect plan, promotional materials and then complete, once the products have passed out of its revenue in this thread, all the basis for cooperation is no longer exists. Ultimately, the key to the effective operation of investment markets will be down to product, it is above the main line to: have an interest and valuable products is the first of its co-operation! So how through effective product management, to maximize the value of the excavation of the product itself to meet the agent’s profit is the large investment needs of enterprises to seriously face a pr